Evaluating only BIND Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Market collapse as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
BIND Therapeutics founded
LAYOFF
Market downturn forces cuts
SHUTDOWN
Bankruptcy: BIND Therapeutics ceases operations
Full Analysis
Free · no account needed
Documented cause
BIND Therapeutics was spun out of MIT and Harvard to commercialize ACCURIN targeted polymeric nanoparticles for cancer drug delivery. After raising 100 million dollars including a 2013 Nasdaq IPO, the lead product failed to show efficacy in clinical trials. The company filed for Chapter 7 bankruptcy in April 2016.
Lesson
“Drug delivery platforms require the payload and the delivery vehicle to both work in humans. ACCURIN was an elegant delivery system for a drug that did not work well enough.”